Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a pivotal Phase 3 study titled ‘The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes).’ The study aims to assess whether retatrutide can significantly reduce major cardiovascular and kidney events in adults with a BMI of 27 kg/m² or higher, who also have atherosclerotic cardiovascular disease and/or chronic kidney disease. This research is significant as it targets two critical health issues prevalent in the obese population.
The intervention being tested is retatrutide, a drug administered subcutaneously, designed to potentially lower the incidence of severe heart and kidney complications. Participants will receive either retatrutide or a placebo, with doses adjusted to the maximum tolerated level.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Both participants and investigators are blinded to the treatment allocation, ensuring unbiased results. The primary purpose of this study is treatment-focused.
The study began on April 30, 2024, and is expected to last approximately five years, with the primary completion date not yet specified. The last update was submitted on June 24, 2025, indicating ongoing progress in recruitment and data collection.
This clinical update could potentially influence Eli Lilly’s stock performance positively, as successful outcomes may lead to a new treatment option in a competitive market focused on cardiovascular and kidney health. Investors should watch for further developments, as positive results could enhance Eli Lilly’s market position against competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.